{"entity":{"id":"bausch-health","kind":"company","name":"Bausch Health","aka":[],"tldr":"Bausch Health (formerly Valeant) is a diversified pharmaceutical company whose oncology-adjacent products include the retinoid bexarotene (Targretin) and imiquimod (Zyclara) for actinic keratosis.","summary":"Bausch Health sells dermatology, gastroenterology, eye health (Bausch + Lomb) and generic medicines. In oncology it holds the US applications for Targretin (bexarotene) in cutaneous T-cell lymphoma and Zyclara and Aldara (imiquimod), the latter approved for superficial basal cell carcinoma and actinic keratosis.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Bausch_Health","links":[{"label":"Official website","url":"https://www.bauschhealth.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Laval, Quebec","country":"CA","companyType":"pharma","website":"https://www.bauschhealth.com","ticker":"BHC","investors":[],"funding":[]},"route":"/companies/bausch-health/","neighbours":{"drug":[{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/"},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/"},{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/"}],"trial":[{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/"}],"paper":[{"id":"paper-mntx-302-thomas-nejm-2008","kind":"paper","name":"Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)","route":"/key-papers/paper-mntx-302-thomas-nejm-2008/"}]}}